H.R. 639 · 114th Congress
Improving Regulatory Transparency for New Medical Therapies Act
Law · 114-89 · Nov 25, 2015Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Became law without a recorded vote. It passed by voice vote or unanimous consent, which don't record how each member voted.
R
PittsSponsor3 cosponsors · 2 D, 1 R
2 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
- House Introduced Feb 2, 2015
- House Passed Mar 16, 2015
- Senate Passed Oct 26, 2015
- House Changes resolved Nov 16, 2015
- President To the President Nov 19, 2015
- President Signed Nov 25, 2015
- Law Nov 25, 2015
Improving Regulatory Transparency for New Medical Therapies Act
What it does: CRS summary · Public Law · Nov 25, 2015
(This measure has not been amended since it was passed by the Senate on October 26, 2015. The summary of that version is repeated here.)
Improving Regulatory Transparency for New Medical Therapies Act
(Sec. 2) This bill amends the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act to delay the effective date of approval of a drug, biological product, or animal drug for which the Food and Drug Administration (FDA) recommends controls under the Controlled Substances Act until the Department of Justice (DOJ) issues a final interim rule for the drug. This delay also applies to conditional approval and indexing of animal drugs.
This bill amends the Controlled Substances Act to require the DOJ to issue a final interim rule for a drug product recommended for controls by the FDA not later than 90 days after DOJ receives a recommendation for controls or the FDA approves the drug. The final interim rule is effective immediately.
For purposes of submitting an application to extend a patent, a drug product recommended for controls is considered to be approved and have permission for commercial marketing and use on the date of FDA approval or the date an interim final rule is issued, whichever is later.
(Sec. 3) Timelines are established for DOJ to either register an applicant to manufacture a controlled substance for a clinical trial or serve an order to show cause upon the applicant.
(Sec. 4) This bill amends the Controlled Substances Import and Export Act to allow exported controlled substances to be re-exported within the European Economic Area.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Improving Regulatory Transparency for New Medical Therapies Act
Latest action (Nov 25, 2015): Became Public Law No: 114-89.
Policy area: Crime and Law Enforcement · Origin: House · Introduced: Feb 2, 2015
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
- House Introduced Feb 2, 2015
- House Passed Mar 16, 2015
- Senate Passed Oct 26, 2015
- House Changes resolved Nov 16, 2015
- President To the President Nov 19, 2015
- President Signed Nov 25, 2015
- Law Nov 25, 2015
No recorded floor vote found.